These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 34373733)

  • 1. Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy.
    Seifert R; Kessel K; Schlack K; Weckesser M; Kersting D; Seitzer KE; Weber M; Bögemann M; Rahbar K
    Theranostics; 2021; 11(17):8143-8151. PubMed ID: 34373733
    [No Abstract]   [Full Text] [Related]  

  • 2. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [
    Seifert R; Kessel K; Schlack K; Weber M; Herrmann K; Spanke M; Fendler WP; Hadaschik B; Kleesiek J; Schäfers M; Weckesser M; Boegemann M; Rahbar K
    Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):1200-1210. PubMed ID: 32970216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SUV
    Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Schlötelburg W; Michalski K; Rowe SP; Pomper MG; Buck AK; Eberlein U; Werner RA
    Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3465-3474. PubMed ID: 37272956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular imaging and biochemical response assessment after a single cycle of [
    Rosar F; Hau F; Bartholomä M; Maus S; Stemler T; Linxweiler J; Ezziddin S; Khreish F
    Theranostics; 2021; 11(9):4050-4060. PubMed ID: 33754047
    [No Abstract]   [Full Text] [Related]  

  • 5. Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving
    Seifert R; Seitzer K; Herrmann K; Kessel K; Schäfers M; Kleesiek J; Weckesser M; Boegemann M; Rahbar K
    Theranostics; 2020; 10(17):7812-7820. PubMed ID: 32685021
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic efficacy, prognostic variables and clinical outcome of
    Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
    Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Performance of RECIP 1.0 Based on [
    Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Higuchi T; Schlötelburg W; Michalski K; Gafita A; Rowe SP; Pomper MG; Buck AK; Werner RA
    J Nucl Med; 2024 Apr; 65(4):560-565. PubMed ID: 38453363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative
    Kuo PH; Morris MJ; Hesterman J; Kendi AT; Rahbar K; Wei XX; Fang B; Adra N; Garje R; Michalski JM; Chi K; de Bono J; Fizazi K; Krause B; Sartor O; Tagawa ST; Ghebremariam S; Brackman M; Wong CC; Catafau AM; Benson T; Armstrong AJ; Herrmann K
    Radiology; 2024 Aug; 312(2):e233460. PubMed ID: 39162634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease?
    Küper AT; Kersting D; Telli T; Herrmann K; Rominger A; Afshar-Oromieh A; Lopes L; Karkampouna S; Shi K; Kim M; Hadaschik B; Darr C; Umutlu L; Fendler WP; Seifert R
    Theranostics; 2024; 14(9):3623-3633. PubMed ID: 38948055
    [No Abstract]   [Full Text] [Related]  

  • 10. Early response monitoring during [
    Neubauer MC; Nicolas GP; Bauman A; Fani M; Nitzsche E; Afshar-Oromieh A; Forrer F; Rentsch C; Stenner F; Templeton A; Schäfer N; Wild D; Chirindel A;
    Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1185-1193. PubMed ID: 38038755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prognostic Value of Posttreatment
    Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L
    J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined
    Suman S; Parghane RV; Joshi A; Prabhash K; Talole S; Basu S
    Prostate; 2021 Nov; 81(15):1225-1234. PubMed ID: 34469602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer.
    Soydal C; Araz M; Urun Y; Nak D; Ozkan E; Kucuk NO
    Q J Nucl Med Mol Imaging; 2021 Sep; 65(3):282-286. PubMed ID: 31602963
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Shagera QA; Artigas C; Karfis I; Critchi G; Chanza NM; Sideris S; Peltier A; Paesmans M; Gil T; Flamen P
    J Nucl Med; 2022 Aug; 63(8):1191-1198. PubMed ID: 34772793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of
    Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
    Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
    [No Abstract]   [Full Text] [Related]  

  • 16. Pre-treatment
    Eisazadeh R; Mirshahvalad SA; Schwieghofer-Zwink G; Hehenwarter L; Rendl G; Gampenrieder S; Greil R; Pirich C; Beheshti M
    Mol Imaging Biol; 2024 Apr; 26(2):360-369. PubMed ID: 38360991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response assessment using
    Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early molecular imaging response assessment based on determination of total viable tumor burden in [
    Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
    Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With Cabazitaxel.
    Shagera QA; Karfis I; Sideris S; Guiot T; Woff E; Martinez-Chanza N; Roumeguere T; Gil T; Flamen P; Artigas C
    Clin Nucl Med; 2023 Sep; 48(9):775-780. PubMed ID: 37385221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.